Circulating tumor cells can reveal genetic signature of dangerous lung cancers Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
Motesanib Effective in Progressive Differentiated Thyroid Disease July 4, 2008 The experimental drug motesanib (under development by Amgen) has shown activity in progressive advanced thyroid cancer in a phase 2 trial in 93 patients.This is one of the largest clinical trials ever conducted in this...
Circulating Tumor Cells Can Reveal Genetic Signature Of Dangerous Lung Cancers A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.'The CTC-chip opens up a whole new field of studying tumors in real time,' says Daniel Haber,...
Promising New Tool to Monitor Lung Cancer Treatment Progress Researchers at Massachusetts General Hospital (MGH) are testing a non-surgical technique that may help doctors monitor how well patients are responding to treatment.Using a device known as a CTC-chip to analyze circulating tumor cells...
Circulating tumor cells can reveal genetic signature of dangerous lung cancers Medicine & Health/ Cancer Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic...
Microchip-based device determines the genetic signature of lung tumors Massachusetts General Hospital (MGH)investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
Report says cancer clinicians should understand and consider the economic impact of new interventions Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of , a peer-reviewed journal of the.The report says...
Trapped Circulating Tumor Cells Track NSCLC Treatment BOSTON, July 2 -- Patient response to non-small-cell lung cancer treatment can be assessed by capturing circulating tumor cells with a microchip, a small study showed.Genotyping the cells had a sensitivity of 92% for mutations that affect...
Circulating tumor cells can reveal genetic signature of dangerous lung cancers , 6:05 PM EST (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of...
Cancer Treatment Clinicians Should Consider Economic Impacts Cancer clinicians should understand and consider the economic impact of new interventions when considering cancer treatment, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal...
Report says clinicians should consider economic impact of new interventions Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal for Clinicians, a peer-reviewed...
A New Citeline Analysis Provides Valuable Clues To Health Of Drug Companies In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing clinical trials activity, and find that...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies In a detailed ranking of companies by ongoing trial activity across six therapeutic areas (autoimmune/inflammation, cardiovascular, CNS, metabolic, infectious diseases, and oncology), this analysis finds that those companies spending in...
20 Compounds That Defined Biotech As we know all too well, the course of a drug candidates clinical development is almost never smooth, and can often be pitted with unanticipated obstacles.Yet, despite this, many drugs manage to not only receive the FDAs blessing, but...
OSI shares rise on Weisel 'Overweight' rating Tarceva, which is approved to treat non-small cell lung cancer and pancreatic cancer and was developed by OSI, is sold by Genentech Inc.Analyst Stephen Willey said Tarceva sales could get a boost from data expected in the second half of...
OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales NEW YORK (AP) - Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical...
OSI shares rise on Weisel 'Overweight' rating Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva.
Tarceva, which...
OSI shares rise on Weisel 'Overweight' rating NEW YORK - Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva.
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f 4:10 PM ET DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to...
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to success in the...
M. D. Anderson and Aureon Laboratories to Evaluate Biomarkers Associated with Non-Small Cell Lung Cancer Business Editors/Health/Medical Writers Aureon's systems pathology platform applies morphometric imaging to formalin-fixed, paraffin-embedded (FFPE) tissue specimens, enabling quantitation and integration of histological attributes and...
